SAN DIEGO — Headlining a top Alzheimer’s conference this week, the pharmaceutical company Biogen will for the first time share the data that led…
After months of delays, Alzheon gears up to present data from their pivotal Phase 3 drug trial, while Athira Pharma pays out a settlement…
This past three months in the Alzheimer’s drug development space have seen a new FDA approval for a symptomatic treatment, a couple failed phase…
In a recent survey, Being Patient put a question to readers: “What is the biggest barrier preventing you from seeking a trial?” The most…
It’s been a big year for Alzheimer’s research. Between July 6 of last year and this July 2, two disease-modifying drugs for Alzheimer’s disease received full…
It can be challenging to find information about Alzheimer’s clinical trials, let alone find trial participants’ first-hand accounts of their experiences. People living with…
Clinical trials and studies scientific experiments that investigate new treatments, lifestyle interventions, or risk factors for developing a disease like Alzheimer’s or dementia. By…
The monoclonal antibody drugs targeting the brain’s amyloid plaques dominated the news cycle in 2023. Eisai and Biogen’s Leqembi was approved by the FDA…
Over 55 million people worldwide have dementia. This mind-robbing condition has a huge impact on society and the economy, so scientists are working hard…
As Dr. Jeff Chen MD, MBA recalled in a recent talk at the 2023 TED Conference in Vancouver, BC, when he was a medical…
Recently, Eli Lilly announced that their anti-amyloid drug solanezumab failed to prevent Alzheimer’s in cognitively healthy older individuals who showed amyloid plaque accumulation in…
With research for the recently FDA-approved Leqembi still in clinical trials and other Alzheimer’s research ongoing, many are considering whether to be a part…
Eisai and Biogen’s new anti-amyloid drug Leqembi was recently approved through the FDA’s accelerated pathway. Now, it’s on the market with a price tag…
While scientists don’t know yet what causes Alzheimer’s, beta-amyloid protein plaques remain one of the prime suspects. While many approaches have focused on clearing…
In February of this year, the Centers for Medicare and Medicaid Services (CMS) released a confusing proposal to dramatically limit insurance coverage for Aduhelm,…